Literature DB >> 19903725

Current concepts in the assessment and treatment of hepatic encephalopathy.

W J Cash1, P McConville, E McDermott, P A McCormick, M E Callender, N I McDougall.   

Abstract

Hepatic encephalopathy (HE) is defined as a metabolically induced, potentially reversible, functional disturbance of the brain that may occur in acute or chronic liver disease. Standardized nomenclature has been proposed but a standardized approach to the treatment, particularly of persistent, episodic and recurrent encephalopathy associated with liver cirrhosis has not been proposed. This review focuses on the pathogenesis and treatment of HE in patients with cirrhosis. The pathogenesis and treatment of hepatic encephalopathy in fulminant hepatic failure is quite different and is reviewed elsewhere.

Entities:  

Mesh:

Year:  2009        PMID: 19903725     DOI: 10.1093/qjmed/hcp152

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  40 in total

Review 1.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

2.  Bile Acid Signaling Is Involved in the Neurological Decline in a Murine Model of Acute Liver Failure.

Authors:  Matthew McMillin; Gabriel Frampton; Matthew Quinn; Samir Ashfaq; Mario de los Santos; Stephanie Grant; Sharon DeMorrow
Journal:  Am J Pathol       Date:  2015-12-09       Impact factor: 4.307

Review 3.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

4.  A SPECIAL MEETING REVIEW EDITIONAdvances in Hepatic Encephalopathy From EASL 2014: A Review of Selected Presentations From the 49th Annual Meeting of the European Association for the Study of the LiverApril 9-13, 2014 • London, United KingdomWith Expert Commentary by: Steven L. Flamm, MDProfessor of Medicine and SurgeryDivision of Gastroenterology and HepatologyChief of the Liver Transplantation ProgranNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

5.  The bile duct ligated rat: A relevant model to study muscle mass loss in cirrhosis.

Authors:  Cristina R Bosoi; Mariana M Oliveira; Rafael Ochoa-Sanchez; Mélanie Tremblay; Gabriella A Ten Have; Nicolaas E Deutz; Christopher F Rose; Chantal Bemeur
Journal:  Metab Brain Dis       Date:  2016-12-15       Impact factor: 3.584

6.  Gli1 activation and protection against hepatic encephalopathy is suppressed by circulating transforming growth factor β1 in mice.

Authors:  Matthew McMillin; Cheryl Galindo; Hae Yong Pae; Gabriel Frampton; Pier Luigi Di Patre; Matthew Quinn; Eric Whittington; Sharon DeMorrow
Journal:  J Hepatol       Date:  2014-07-18       Impact factor: 25.083

7.  Clinical profile, natural history, and predictors of mortality in patients with acute-on-chronic liver failure (ACLF).

Authors:  Ivana Mikolasevic; Sandra Milic; Mladen Radic; Lidija Orlic; Zeljka Bagic; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2015-03-28       Impact factor: 1.704

8.  Lactulose decreases neuronal activation and attenuates motor behavioral deficits in hyperammonemic rats.

Authors:  Natália Ferreira Mendes; Flora França Nogueira Mariotti; José Simões de Andrade; Milena de Barros Viana; Isabel Cristina Céspedes; Márcia Regina Nagaoka; Luciana Le Sueur-Maluf
Journal:  Metab Brain Dis       Date:  2017-09-05       Impact factor: 3.584

9.  Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.

Authors:  Maria Garrido; Jelena Skorucak; Daniela Raduazzo; Matteo Turco; Giuseppe Spinelli; Paolo Angeli; Piero Amodio; Peter Achermann; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2016-05-19       Impact factor: 3.584

Review 10.  Effects of bile acids on neurological function and disease.

Authors:  Matthew McMillin; Sharon DeMorrow
Journal:  FASEB J       Date:  2016-07-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.